MedTrace Logo

Paxlovid for Treatment of Long Covid

NCT05576662 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2025-09-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare whether being treated with nirmatrelvir plus ritonavir for 15 days works better than being treated with placebo plus ritonavir to reduce severe symptoms of Long Covid.

Participants will have 5 planned visits to the study clinic over 15 weeks and will take the drug (or placebo) for the first 15 days.

This study uses the term post-acute sequelae of SARS-CoV-2 (PASC), which is another name for "Long Covid."

Conditions

  • Post-acute Sequelae of SARS-CoV-2 Infection
  • Long COVID

Interventions

DRUG

Nirmatrelvir

Two 150 mg tablets taken by mouth every 12 hours

DRUG

Placebo

Two tablets containing placebo matching nirmatrelvir taken by mouth every 12 hours

DRUG

Ritonavir

One 100 mg capsule taken by mouth every 12 hours

Sponsors & Collaborators

Principal Investigators

  • Upinder Singh, MD · Stanford University

  • Linda Geng, MD, PhD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-08
Primary Completion
2023-08-14
Completion
2023-09-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05576662 on ClinicalTrials.gov